Operating
Stock-Based Comp
Biogen Stock-Based Comp increased by 40.9% to $84.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.7%, from $81.00M to $84.00M. Over 4 years (FY 2021 to FY 2025), Stock-Based Comp shows an upward trend with a 5.1% CAGR.
Analysis
StatementCash Flow Statement
SectionOperating
CategoryEfficiency
SignalContext dependent
VolatilityStable
First reportedQ1 2014
Last reportedQ1 2026
How to read this metric
Increasing levels may indicate a focus on talent retention but can also signal potential shareholder dilution.
Detailed definition
This represents the value of equity-based awards granted to employees as part of their total compensation package. Since...
Peer comparison
Standard across large-cap corporations; varies based on corporate compensation philosophy.
Metric ID:
stock_based_compensationHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $54.10M | $55.70M | $58.80M | $67.60M | $55.70M | $63.60M | $67.20M | $75.60M | $71.50M | $62.20M | $54.90M | $72.80M | $70.60M | $72.70M | $75.10M | $81.00M | $74.90M | $75.30M | $59.60M | $84.00M |
| QoQ Change | — | +3.0% | +5.6% | +15.0% | -17.6% | +14.2% | +5.7% | +12.5% | -5.4% | -13.0% | -11.7% | +32.6% | -3.0% | +3.0% | +3.3% | +7.9% | -7.5% | +0.5% | -20.8% | +40.9% |
| YoY Change | — | — | — | — | +3.0% | +14.2% | +14.3% | +11.8% | +28.4% | -2.2% | -18.3% | -3.7% | -1.3% | +16.9% | +36.8% | +11.3% | +6.1% | +3.6% | -20.6% | +3.7% |
Range$54.10M – $84.00M
CAGR+9.7%
Avg YoY Growth+6.5%
Median YoY Growth+4.9%
Stock-Based Comp at Other Companies
Frequently Asked Questions
- What is Biogen's stock-based comp?
- Biogen (BIIB) reported stock-based comp of $84.00M in Q1 2026.
- How has Biogen's stock-based comp changed year-over-year?
- Biogen's stock-based comp increased by 3.7% year-over-year, from $81.00M to $84.00M.
- What is the long-term trend for Biogen's stock-based comp?
- Over 4 years (2021 to 2025), Biogen's stock-based comp has grown at a 5.1% compound annual growth rate (CAGR), from $238.60M to $290.80M.
- What does stock-based comp mean?
- The non-cash cost of paying employees with company stock instead of cash.